# The Partner Choice, Not the Drug, Sank ORIC's Stock - Date: 2026-04-01 - Category: Biotech & Life Sciences ORIC picked a sensible dose for its prostate cancer drug. The market dropped the stock 27% because the real question is why the company chose darolutamide as its combination partner — and what Pfizer found with a similar drug first. ---